GMV’s radiotherapy planner, radiance, aids gastric-cancer research in Poland’s Medical University of Lublin
GMV’s inhouse intraoperative radiotherapy (IORT) planner, radiance™, conquers yet another European country. Poland’s Medical University of Lublin, convinced by its proven efficiency, is the latest to take up the planner.
The planner is to be provided jointly with the Mobetron® linear accelerator (LINAC) of the North American company IntraOp®, designed to deliver electron-beam Intraoperative Radiation Therapy (IORT). Together the two machines will be used to treat gastric tumors, a cancer that now takes a toll of 700,000 a year around the world.
The parameters and indicators provided by radiance™ mean that planning of the personalized application of Mobetron®’s high-energy electron beam can be adjusted to suit the form of each particular tumor, destroying the cancerous cells without harming the surrounding healthy tissue. This will help specialists of Lublin’s University Hospital in their research into locally advanced gastric cancers.
Professor Wojciech P. Polkowsiki, director of the surgical oncology department, points out that, in stage III gastric cancer, IORT-directed surgery in combination with systemic perioperative therapy could improve the survival rate of patients with gastric tumors. "Our hospital is delighted to be able to work with Mobetron®, together with in-built radiance™, enabling us to plan treatment in 3D… Promising tests have shown that IORT improves the local control and survival rate in the treatment of rectal cancers and advanced pancreatic cancers. We now hope to achieve similar results in gastric cancers, where death rates in Poland and Eastern Europe as a whole are fairly high.”
About radiance™
radiance™ is the world’s only intraoperative radiation therapy (IORT) planner. It boosts the safety of IORT, helping the specialist to make a complete analysis of the patient and improving pre-surgery decision-making. This favors identification of the perfect treatment for each particular patient.
Its groundbreaking software calculates the exact radiotherapy-application parameters in the operating theater itself but before the operation goes ahead. It provides high-quality Multiplanar Reformation (MPR) images and three-dimensional (3D) vision of the patient, enabling treatment results to be simulated beforehand. This information offers all the necessary information for documenting the operation and keeping a historical record of radiation doses.
Collaborating with GMV in the evaluation of radiance™ are Mannheim University Hospital (Germany), Hospital Doctor Negrín (Las Palmas, Spain), Oncopôle (Toulouse, France), Cleveland Clinic (Cleveland, USA), Weill Cornell Medical College and Loyola Medical Center (Chicago, USA).
radiance™ has been taken up by Spanish hospitals like Hospital Universitario Ramón y Cajal (Madrid), Hospital de La Luz (Madrid), Hospital General Universitario Gregorio Marañón (Madrid), Hospital Provincial (Castellón) and Hospital Universitario de Gran Canaria Doctor Negrín (Las Palmas).
Outside Spain radiance™ is now up and running in the University Cancer Institute of Toulouse Oncopole (France), the Hospital Pugliese Ciaccio (Cantazaro, Italy), the European Institute of Oncology (Milan, Italy), Cleveland Clinic (USA), Jackson Memorial Hospital (Miami, USA), New York–Presbyterian Hospital (USA), Mount Sinai Hospital (New York, USA), King Fahad Specialist Hospital (Dammam, Saudi Arabia) and King Fahad Medical City (Riyadh, Saudi Arabia), among others.
radiance™ has been patented under the number PCT/ES2008/000240 and registered as a brand with the name of intraplan radiance® since 2008. In 2011 radiance™ obtained the CE marking certificate, authorizing its marketing in all EU member states. Then, in 2012, GMV received FDA clearance for marketing radiance™ throughout the USA.